Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yilong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3911-2830; OpenAlex author ID A5100600202. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 14

  1. The lncRNA ST18-AS1 suppresses pancreatic cancer progression by enhancing ST18 mRNA stability through anchoring FUS in the cytoplasm. Co-author DOI 10.1038/s41388-025-03455-4↗
  2. Dual Starvations Induce Pyroptosis for Orthotopic Pancreatic Cancer Therapy through Simultaneous Deprivation of Glucose and Glutamine. Co-author DOI 10.1021/jacs.4c03478↗
  3. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  4. Comprehensive Analysis of Necroptosis in Pancreatic Cancer for Appealing its Implications in Prognosis, Immunotherapy, and Chemotherapy Responses. Co-author DOI 10.3389/fphar.2022.862502↗
  5. Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fgene.2021.747270↗
  6. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00612↗
  7. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-019-1278-9↗
  8. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  9. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. Co-author DOI 10.1007/s10637-017-0508-2↗
  10. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗
  11. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Co-author DOI 10.18632/oncotarget.18669↗
  12. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Co-author DOI 10.1007/s13277-015-4552-2↗
  13. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Co-author DOI 10.18632/oncotarget.11517↗
  14. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Co-author DOI 10.1016/j.bcp.2014.01.041↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bei Sun · 11 shared papers, 2014–2022 · strength 0.92
  2. Rui Kong · 8 shared papers, 2016–2022 · strength 0.67
  3. Yongwei Wang · 7 shared papers, 2016–2024 · strength 0.62
  4. Jisheng Hu · 6 shared papers, 2017–2022 · strength 0.54
  5. Shangha Pan · 7 shared papers, 2014–2022 · strength 0.53
  6. Gang Wang · 3 shared papers, 2019–2025 · strength 0.50
  7. Le Li · 5 shared papers, 2018–2022 · strength 0.47
  8. Hongze Chen · 4 shared papers, 2018–2022 · strength 0.37
  9. Zhongjie Zhao · 3 shared papers, 2019–2022 · strength 0.30
  10. Yan Jin · 1 shared paper, 2025 · strength 0.24
  11. Long Cheng · 1 shared paper, 2025 · strength 0.24
  12. Chundong Cheng · 2 shared papers, 2019–2022 · strength 0.21
  13. Xinlong Wang · 1 shared paper, 2024 · strength 0.18
  14. Ping'an Ma · 1 shared paper, 2024 · strength 0.18
  15. Kun Fang · 1 shared paper, 2022 · strength 0.17
  16. Yongwei Wang · 2 shared papers, 2014–2022 · strength 0.16
  17. Le Li · 2 shared papers, 2017–2019 · strength 0.16
  18. Kai-Song Bai · 1 shared paper, 2021 · strength 0.13
  19. Xuewei Bai · 1 shared paper, 2021 · strength 0.13
  20. Gang Wang · 1 shared paper, 2022 · strength 0.13
  21. Tao Zhang · 1 shared paper, 2022 · strength 0.13
  22. Danxi Liu · 1 shared paper, 2022 · strength 0.13
  23. Zonglin Liu · 1 shared paper, 2022 · strength 0.13
  24. Guanqun Li · 1 shared paper, 2018 · strength 0.07
  25. Huan Liu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.